Clinical registration application for tAEST16001 new drug submitted by Xiang Xue Pharmaceuticals to the State Drug Administration has been approved

recently, Guangzhou XiangxuePharmaceutical(http://limited shares of the company(http://("Shan Xue Pharmaceuticals") announced that its subsidiary, Guangdong Xiangxue PrecisionMedical(http://Technology Co., Ltd("Shan Xue Precision") to the NationalMedicines(http://Regulatory Authority (NMPA
) http:// the http:// of the http://(http://Clinical Registration Application (IND) has been approved for solid tumors such as soft tissue sarcoma with an ensometric genotype of HLA-A-02:01, tumor antigen NY-ESO-1Athenex20187Axis Therapeutics,TAEST,Axis
(http://
。 October 2018, the two parties jointly announced that preliminary clinical results from patients treated with TCR-T cell therapy (TAEST) showed encouraging positive signs Of the six patients treated, two showed partial reactions, and four showed stable performance, two of whom had significant tumor necrosis shortly after treatment In addition, the therapy also showed controlled safety and did not produce adverse reactions to the central nervous system 　　Athenex has established a research and development platform for T-cell Receptor Engineering T-Cell Therapy (TCR-T) to address problems in the treatment of Chimeric Antigen Receptor (CAR) T-cell Therapy Unlike CAR-T therapy, which targets antigens in both diseased tissue scanted and healthy (http:// tissues, TCR-T therapy can highly selectively target tumor-related antigens that appear only on the surface of cancer cells TAEST16001 targeted target cancer-testicular antigen NY-ESO-1 was found in the 1990s, and studies have shown that the antigen does not express low expression in normal tissues, while abnormal expression in solid tumors such as epithelial ovarian cancer